Jiangsu Deweilan Completes Nearly RMB 100 Million Series B Financing to Build a Leading Hemostatic Innovation Materials Platform

VCBeat (WeChat ID: vcbeat) has recently learned that Deviceland (DVL), a leading domestic manufacturer of intraoperative hemostatic products, has announced the completion of its Series B financing. The round was co-led by Qingdao Shuimu Zijing, Qingdao Shuimu Ziteng, and Hainan Jinhui Feng, raising nearly RMB 100 million. The funds will be primarily used to advance product research and development, expand production lines, and increase market investment.

JiangSu Deviceland Medical Instrument Co., Ltd. was established in 2012 at the China Medical City in Taizhou, Jiangsu Province. Leveraging nearly eight years of specialized domestic and international experience in medical device sales from its team, and relying on the platform of the only national-level professional pharmaceutical industrial park in China, the company rapidly established an innovative R&D center for hemostatic materials that integrates research and development, manufacturing, registration services, and product sales. Currently, Deviceland has obtained medical device registration certificates for four products, including "Polysaccharide Hemostatic Materials" and "High-Frequency Electrosurgical Units and Electrodes." This achievement completes its product layout across both passive and active domains of hemostatic materials, providing comprehensive coverage of intraoperative hemostatic consumables. The domestic market for intraoperative hemostasis features high demand, diverse clinical departments, and limited segmentation; in certain aspects, the performance and quality of domestically produced products still fail to meet clinical needs. With advancements in scientific research and continuous market segmentation, this sector is poised to capture an annual market share exceeding RMB 50 billion. Through the market expansion of its core products, Deviceland has secured a significant position in the field of intraoperative hemostasis and established a brand image representing high-quality Chinese manufacturing, positioning itself for rapid growth in market share in the future.

Deviceland boasts a sales team with extensive industry experience and strong execution capabilities, establishing a nationwide sales network covering all provinces and regions across China within one year. Leveraging high-performance products, a solid brand foundation, and resource advantages, the company achieved rapid growth in sales performance, with the average monthly sales volume in 2021 reaching twice that of the same period in the previous year. In the future, Deviceland will further leverage its resources in industry-academia-research collaboration to drive valuable local innovations. By combining these efforts with academic exchanges and basic education training, the company will aggressively introduce new products to the market, expanding its reach to meet the needs of a broader population and benefiting public health. Despite the impact of the COVID-19 pandemic on the global healthcare industry in 2020, Deviceland maintained sustained and rapid growth in the niche sector of medical hemostasis. Driven by a new round of investment, Deviceland continues to vigorously expand its market presence and consistently launch novel hemostatic materials that align with market demands.

Regarding the success of this round of financing, the Company’s Board of Directors expressed its gratitude to the investors for their trust, and to friends from all sectors of society who have long paid attention to and supported Deviceland. Deviceland will take this as motivation to continue dedicating itself wholeheartedly to the business of high-quality medical surgical hemostatic materials, providing physicians with premium products and helping patients overcome illness.

As the lead investor in this round, a Tsinghua-affiliated industrial fund stated that Deviceland is a company that aligns perfectly with its investment philosophy. It not only possesses the essential qualities of an outstanding medical technology enterprise but also demonstrates the social responsibility to serve doctors and patients and promote the development of specialized fields within medicine. The fund believes that following this round of financing, Deviceland will further optimize its operations, consolidate its market position, and enhance its influence and industry standing. Capital will continue to drive the mutual growth of Deviceland and the intraoperative hemostasis industry.

Deviceland has currently launched its Series C financing round. The funds raised will be used to further expand production capacity for hemostatic materials, promote market development, establish a large-scale R&D center and a new production base in Shanghai, and launch 3–4 high-end hemostatic products over the next two to three years. These initiatives aim to capture a larger market share and accelerate Deviceland’s emergence as a leading enterprise in innovative hemostatic materials in China.